Dr. Lal Path Labs Ltd. — Q4 FY26 earnings call

Call held 6 May 2026

Management summary

Dr. Lal Pathlabs reported a strong Q4 and FY26, with double-digit revenue growth driven by volume expansion and strategic initiatives. The company expanded its network, launched new premium services like Sovaaka, and hosted a major medical conference. While Q4 PAT saw a decline due to comparative exceptional items in the prior year, underlying margins remained healthy, and management provided an optimistic outlook for FY27 with early to mid-teens revenue growth and stable margins, supported by continued investments in infrastructure and M&A.

Highlights

  • Strong revenue growth in Q4 FY26 at 16.6% YoY, reaching ₹703 crores.

  • Full year FY26 revenue grew 12.2% YoY to ₹2,763 crores, driven by sample volume growth of 10.4%.

  • Excluding one-time items, FY26 EBITDA margin was 28.3% with 12.5% growth, and PAT margin was 19.3% with 17.9% growth.

  • Successful launch of 'Sovaaka' for AI-powered precision health screening and hosting of 'Medllumina 2026' to reinforce scientific leadership.

  • Expanded operational footprint by adding 14 new labs and over 1,100 collection centers in FY26.

  • Maintained a strong balance sheet with net cash and cash equivalents of ₹1,526 crores.

Concerns

  • PAT for Q4 FY26 was ₹132 crores, down from ₹156 crores in Q4 FY25, partly due to the absence of a one-time benefit from Suburban Diagnostics liquidation.

  • Potential future impact on supply chain and reagent costs due to ongoing Middle East war, though currently managed with ample inventory.

Key financials

  1. Revenue Q4 FY26 ₹703 Cr +16.6%YoY
  2. Revenue FY26 ₹2,763 Cr +12.2%YoY
  3. EBITDA Q4 FY26 ₹187 Cr +10.5%YoY
  4. EBITDA Margin Q4 FY26 26.6%
  5. EBITDA FY26 ₹752 Cr +8.2%YoY
  6. EBITDA Margin FY26 27.2%
  7. PAT Q4 FY26 ₹132 Cr
  8. PAT Margin Q4 FY26 18.8%
  9. PAT FY26 ₹510 Cr
  10. PAT Margin FY26 18.4%
  11. EPS FY26 ₹30.2
  12. Sample Volume Growth Q4 FY26 0.129 decimal_fraction
  13. Sample Volume Growth FY26 0.104 decimal_fraction
  14. Revenue per patient Q4 FY26 ₹956 +7.8%YoY
  15. Test per patient Q4 FY26 3.21
  16. Net Cash & Equivalents ₹1,526 Cr

What they filed

Q1 FY27: revenue up 19.2%, net profit up 28.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue631 569 577 641 700 +11%632 +11%675 +17%764 +19%
EBITDA194 151 159 183 215 +11%174 +15%182 +14%238 +30%
Net profit129 105 148 129 146 +13%92 −12%141 −5%166 +29%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • B2C
    75% Contribution to Revenue
  • Tier 3+ Geographies
    39% Contribution to Revenue

Capital allocation

high confidence
  • Capex ₹100 Cr
    • Maintenance capex
    • New labs (12-15)
    • 1-2 Radiology centers
    • Precision lab investment
    Anshul, for capex, I think we are planning to be in the range of Rs. 100 crore - Rs. 120 crore kind of capex for the next year. ... Yes. We are planning to have 1 or 2 radiology centres. So that includes in there. This Rs. 100 crore - Rs. 120 crore is one is maintenance capex. Obviously, another is we are opening like we opened 14 labs in this year. Next year also, we are looking 12 to 15 labs, another labs. And one you know, another investment we are making in our precision lab. So those are the additional investment in addition to maintenance capex.
  • Debt Debt disclosed
    We continue to maintain a strong balance sheet with our net cash and cash equivalents standing at Rs. 1,526 crore, providing ample liquidity for future growth and M&A.
  • Dividend ₹4/share (final)
    Further, I am pleased to share that the Board of Directors have approved the final dividend of 40%, that is Rs. 4 per share, taking the total dividend for the year to Rs. 20.5 per share, that is 280% after adjustment of bonus issue of 1:1 in Q3 FY26.
  • M&A Shahbazkers Diagnostic Centre Acquisition · Closed · Consideration ₹[object Object] (undisclosed)

    Acquired to fill a micro-market presence gap in Mumbai where Dr. Lal PathLabs or Suburban had no significant presence, and to build stronger presence in Mumbai and the West region.

    Small asset, not large, with a turnover of Rs. 6 crore. Includes pathology with basic radiology (sonography and X-ray).

    Good evening and thanks for the opportunity, A couple of questions on the recent asset acquisition of Shahbazkers in Mumbai. Just wanted to know, I mean, what is the business mix over there? What is the share of Radio and Path? Are 100% of revenue considering walk-in patient? And what has been the rationale of Dr. Lal acquiring this asset? ... Total deal size is about Rs. 20 crore for this asset. ... We have not disclosed the EBITDA margin as of now. We have disclosed it is about a Rs. 6 crore kind of turnover, top line. It is a small asset, it is not large.
  • Liquidity Cash ₹1,526 Cr Ample liquidity for future growth and M&A.
    We continue to maintain a strong balance sheet with our net cash and cash equivalents standing at Rs. 1,526 crore, providing ample liquidity for future growth and M&A.

Guidance & targets

Revenue

  • Revenue Growth Revenue · FY27 · High confidence early to mid-teens
    We are entering FY27 with strong operational momentum, a strengthened digital infrastructure, and a clear pathway towards sustaining early to mid-teens revenue growth.

    — Shankha Banerjee

Margin

  • EBITDA Margin Margin · FY27 · High confidence 27%-28%
    While for the next year, as we are closing this year 27.2%, even after taking the one-time charge of Rs. 30 crore on account of new Labour Code. So, we are hopeful for next year also, we are looking something similar margin like between 27% to 28%.

    — Ved Goel

Capex

  • Total Capex Capex · FY27 · High confidence ₹100-120 crores
    Anshul, for capex, I think we are planning to be in the range of Rs. 100 crore - Rs. 120 crore kind of capex for the next year.

    — Ved Goel

Network Expansion

  • New Labs Network Expansion · FY27 · High confidence 12-15 labs
    Next year also, we are looking 12 to 15 labs, another labs.

    — Ved Goel

  • New Radiology Centers Network Expansion · FY27 · High confidence 1-2 centers
    Yes. We are planning to have 1 or 2 radiology centres. So that includes in there.

    — Ved Goel

What to watch in Q1 FY27

FY27 Revenue Growth

next quarter
Current FY26 growth 12.2%
Target Early to mid-teens growth

Why it matters

To confirm the company's ability to accelerate growth as guided, indicating market share gains and successful execution of expansion strategies.

We are entering FY27 with strong operational momentum, a strengthened digital infrastructure, and a clear pathway towards sustaining early to mid-teens revenue growth.

Risks & concerns

  • Impact of Middle East war on supply chain and reagent costs

    medium

    Management stated they have ample inventory for 3-4 months and long-term contracts, but acknowledged potential future impact if the war continues due to reliance on imported reagents and consumables.

    Analyst acknowledged

  • Competitive intensity in Mumbai market

    low

    Analyst noted Mumbai's crowded lab market; management acknowledged this but emphasized opportunities for growth in micro-markets and unorganized segments.

    Analyst acknowledged

Q&A highlights

6 direct
Shahbazkers acquisition details and rationale Direct
Right. I will take the last part first, the reason we have acquired this asset is this is quite an old operating lab. It has got a legacy of over 45 years in that geography. And it is in a micro market in Mumbai, where we actually with either Lal PathLabs or Suburban do not really have a significant presence. So, this is going to add to our portfolio in that market, given that we are looking at really building our presence strongly in Mumbai and the West region.

Clarifies the strategic rationale behind the recent acquisition in Mumbai, highlighting market gap filling and regional expansion.

Asked by Tausif Shaikh

Sustainability of margins and FY27 outlook Direct
While for the next year, as we are closing this year 27.2%, even after taking the one-time charge of Rs. 30 crore on account of new Labour Code. So, we are hopeful for next year also, we are looking something similar margin like between 27% to 28%.

Provides explicit EBITDA margin guidance for FY27, indicating stability despite ongoing investments.

Asked by Amey Chalke

Plans for price hikes Partial
The price hike, we have said that we have completed 3 years since we took our last price increase. But we also said that we will kind of wait and watch, especially because we have taken a decision to pass on the GST-related benefit. A few quarters, we will wait and watch and see how the market is reacting and what position we are in, how is our business growing? How is the competitive situation looking like? I think basis that maybe we will decide whether we need to take a price increase or not. But definitely, if it is there, it is a few quarters away. It is not something which is immediately on the cards.

Indicates that a price hike is not immediate and depends on market conditions, impacting future revenue per test.

Asked by Amey Chalke

Contribution of Tier 3/4 geographies to realization Direct
The pricing in that cluster is actually the same. It is not as if I am going to a Tier 3 market naturally means that pricing is going to be different. The cluster pricing remains the same and parallelly, even when I am going into the Tier 3, Tier 4 towns, with more access, we will be able to sell our health packages, preventive check-ups and all of those, which even on a revenue side per patient side is slightly higher revenue. So I think there are those factors there. So as of now, it has not been dilutive, and we do not believe it is going to be dilutive going forward as well.

Clarifies that expansion into Tier 3/4 markets is not dilutive to revenue per patient due to cluster pricing and health package sales.

Asked by Anshul Agrawal

Impact of Middle East war on raw material prices and supply chain Partial
Bino, as of now, no, because we are, obviously, we have ample sufficient inventory for the next 3-4 months, and we have long-term contracts as well. Having said that, I cannot comment, I mean, what happen after 3-4 months. If this war continues, obviously, there will be some impact may come on our supply chain. I mean, because we import most of our reagents and consumables also, there are linkages with oil and all that stuff. But as of now, we are able to maintain. But yes, in future, I do not have visibility right now.

Highlights a potential future risk to the supply chain and costs, despite current mitigation measures.

Asked by Bino Pathiparampil

Plans for Dubai subsidiary and international expansion Direct
Right now, I think the idea is to incorporate a holding company kind of or a company in Dubai, which can also maybe operate as a holding company for the region. Now in terms of our expansion plan, M&A opportunity can also be evaluated. That is always on the cards. But yes, I think both organic and inorganic can be looked at.

Outlines the strategic intent behind the Dubai subsidiary, indicating a broader regional expansion strategy including potential M&A.

Asked by Gaurav Tinani

Reclassification of employee expenses and tax rate Direct
This cost was in the nature of courier and transportation costs, which was grouped under employee benefit, which has been regrouped as per the nature of the expenses. This is the cost which has been regrouped from employee benefit to other expenses. ... There is a reversal of deferred tax in this quarter on account of some income tax assessment has been done, we got the refund and accordingly, we have reversed. But as I mentioned, tax rate is same, which is around 25%, nothing changing.

Clarifies accounting adjustments for expenses and tax, ensuring investors understand the underlying financial performance.

Asked by Gaurav Tinani

Suburban collection model transition and margin profile Direct
On the collection network, now I think the transitions that were to be made have mostly been done. Now the Suburban expansion is also happening mostly through a franchised setup. However, there will be certain geographies where there will be company-owned collection network also that we will consider. But primarily, that whole transition towards having more centers to franchisees is already kind of underway and mostly done, so that is one. I think on the margin, maybe Ved can answer. ... On margins, as I mentioned, we are not tracking separately because this is no more separate entity. But margins, obviously, for different geography, different margin structure, even let us suppose, West as a whole, if we compare Delhi NCR v/s West, obviously, margins are different. But in spite of that, we are looking the margins on an overall basis as a company is in between of whatever 27%-28% margin.

Provides an update on the integration and operational model of Suburban Diagnostics and its contribution to overall company margins.

Asked by Hafeez Patel

2 min read 6 chapters

Detailed narrative

Q4 & FY26 Performance Overview

Dr. Lal Pathlabs concluded FY26 on a strong note, reporting a Q4 revenue of ₹703 crores, marking a 16.6% year-on-year growth. For the full fiscal year 2026, the company achieved a revenue of ₹2,763 crores, growing 12.2% over FY25. This performance was primarily driven by robust sample volume growth, which stood at 12.9% in Q4 and 10.4% for the full year, underscoring the resilience of its business model and patient preference.

Strategic Initiatives & Scientific Leadership

A significant highlight of the quarter was the successful hosting of Medllumina 2026, an international medical conference focusing on 'New Era of Diagnostics' in high complexity domains like Oncogenomics and Transplant Immunology. The company also launched 'Sovaaka', a premium wellness brand offering AI-powered Precision Health Screening, marking a foray into personalized health management. These initiatives reinforce Dr. Lal Pathlabs' scientific leadership and accelerate the adoption of high-end specialized testing.

Operational Expansion & Network Growth

The company successfully executed its expansion plan for FY26, adding 14 new labs and over 1,100 collection centers across the country. This expansion, coupled with the integration of cutting-edge AI diagnostic tools, positions the company to meet rising healthcare demand. The preventive healthcare brand, Swasthfit, contributed 27% to total revenue in FY26, proving to be a critical lever for B2C growth, which now accounts for 75% of the company's revenue.

Financial Performance & Margins

EBITDA for Q4 FY26 was ₹187 crores, growing 10.5% with a margin of 26.6%. For the full year, EBITDA stood at ₹752 crores, with a margin of 27.2%. Excluding one-time costs of ₹30 crores related to the new Labour Code and an exceptional benefit of ₹41 crores in Q4 FY25, the adjusted FY26 EBITDA margin was 28.3% and PAT margin was 19.3%. Management indicated that investments in infrastructure, A&P, and new labs are ongoing, with a target to maintain FY27 EBITDA margins between 27%-28%.

Capital Allocation & M&A

Dr. Lal Pathlabs maintains a strong balance sheet with net cash and cash equivalents of ₹1,526 crores. The Board approved a final dividend of ₹4 per share, bringing the total FY26 dividend to ₹20.5 per share. The company acquired Shahbazkers Diagnostic Centre in Mumbai for ₹20 crores, a small asset with ₹6 crores turnover, to strengthen its presence in a micro-market. For FY27, the company plans a capex of ₹100-120 crores, allocated for 12-15 new labs, 1-2 radiology centers, a precision lab, and maintenance.

Outlook & Future Strategy

The company is confident in achieving early to mid-teens revenue growth for FY27, driven by sustained double-digit growth in Delhi NCR and a pickup in the Suburban business. The expansion of lab and collection networks over the past two years is expected to mature and contribute to future growth. The company is also exploring international expansion, with the incorporation of a holding company in Dubai to facilitate regional growth, including potential M&A opportunities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls